Celcuity (NASDAQ:CELC) Price Target Cut to $150.00 by Analysts at Stifel Nicolaus

Celcuity (NASDAQ:CELC) had its price target trimmed by Stifel Nicolaus from $175.00 to $150.00 in a report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company reduced their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Craig Hallum restated a “buy” rating and issued a $178.00 price target on shares of Celcuity in a research note on Wednesday, July 15th. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Leerink Partners set a $155.00 price objective on shares of Celcuity in a report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and an average target price of $153.64.

Celcuity Stock Up 6.2%

Shares of NASDAQ CELC opened at $92.00 on Friday. Celcuity has a 1 year low of $44.42 and a 1 year high of $151.02. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of -21.40 and a beta of 0.20. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The stock’s 50-day simple moving average is $93.88 and its 200-day simple moving average is $108.45.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, equities analysts anticipate that Celcuity will post -3.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC bought a new stake in shares of Celcuity in the 1st quarter valued at approximately $38,000. EverSource Wealth Advisors LLC lifted its stake in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Celcuity during the fourth quarter worth $42,000. PNC Financial Services Group Inc. increased its stake in Celcuity by 20.1% during the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after purchasing an additional 86 shares during the last quarter. Finally, KBC Group NV acquired a new stake in shares of Celcuity during the first quarter worth $64,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.